2016 a breakthrough year for ISAB
Dow Chemical Group and King’s College London (KCL) purchased PreciseInhale, and the number of client posters and publications validating the system grew rapidly. ISAB CEO Fredrik Sjövall explains why 2016 was a year of milestones.
“PreciseInhale, our dry powder technology, was bought by key players, whilst previous purchasers like Chiesi made major breakthroughs with its help,” says Fredrik Sjövall, “we have clearly put the first critical bricks in place, building a strong foundation for further growth. It is truly exciting to be part of bringing this technology into the future!”
Both KCL and Karolinska Institute have published key findings where PreciseInhale has played a central role—highlighting how the technology is gaining increasing scientific status and acceptance.
DissolvIt, ISAB’s in vitro simulation technology, receives patent from the EPO (European Patent Office)
King’s College London purchase PreciseInhale, King’s Professor Ben Forbes: “ISAB are highly expert… Their bespoke engineered kit is excellent.”
Inhaled pharma leaders and ISAB clients Chiesi become the first to complete two long-term clinical studies on a triple combination COPD treatment. Chiesi uses PreciseInhale extensively in its inhaled products R&D.
ISAB founder and CSO Per Gerde invited to deliver keynote abstract at the 11th International Particle Toxicology Conference in Singapore.
Dow Chemical Group purchases PreciseInhale for its work in Toxicology and Environmental Research. Dr Jon Hotchkiss at Dow, says: “…I am very excited about incorporating PreciseInhale into our research.”
Global scientists travel to Stockholm for Experiences of Aerosol Exposure, a one-day seminar with Per Gerde and guest speakers.
King’s College London presents a DDL27 poster on PreciseInhale administering Flixotide to guinea pigs: ’Comparison of bronchoconstrictor responses to AMP and adenosine in sensitized guinea pigs using the PreciseInhale® system for generation and administration of dry powder aerosols’